XLY Fundamental Analysis - AUXLY CANNABIS GROUP INC

Fundamental Rating

Taking everything into account, XLY scores 5 out of 10 in our fundamental rating. XLY was compared to 32 industry peers in the Pharmaceuticals industry. While XLY is still in line with the averages on profitability rating, there are concerns on its financial health. XLY is growing strongly while it is still valued neutral. This is a good combination!

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XLY was profitable.

In the past year XLY had a positive cash flow from operations.

XLY had negative earnings in each of the past 5 years.

In multiple years XLY reported negative operating cash flow during the last 5 years.

1.2 Ratios

With an excellent Return On Assets value of 10.86%, XLY belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.

XLY has a Return On Equity of 20.44%. This is amongst the best in the industry. XLY outperforms 96.88% of its industry peers.

The Return On Invested Capital of XLY (6.44%) is better than 87.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	10.86%
ROE	20.44%
ROIC	6.44%

ROA(3y)-20.84%

ROA(5y)-18.51%

ROE(3y)-81.82%

ROE(5y)-60.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XLY has a better Profit Margin (20.15%) than 93.75% of its industry peers.

Looking at the Operating Margin, with a value of 9.65%, XLY belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.

XLY's Gross Margin of 43.74% is fine compared to the rest of the industry. XLY outperforms 62.50% of its industry peers.

XLY's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	9.65%
PM (TTM)	20.15%
GM	43.74%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y29.45%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XLY is destroying value.

Compared to 1 year ago, XLY has more shares outstanding

XLY has more shares outstanding than it did 5 years ago.

XLY has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.84, we must say that XLY is in the distress zone and has some risk of bankruptcy.

XLY's Altman-Z score of -0.84 is in line compared to the rest of the industry. XLY outperforms 50.00% of its industry peers.

XLY has a debt to FCF ratio of 3.08. This is a good value and a sign of high solvency as XLY would need 3.08 years to pay back of all of its debts.

The Debt to FCF ratio of XLY (3.08) is better than 87.50% of its industry peers.

A Debt/Equity ratio of 0.09 indicates that XLY is not too dependend on debt financing.

XLY has a Debt to Equity ratio of 0.09. This is in the better half of the industry: XLY outperforms 68.75% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	3.08
Altman-Z	-0.84

ROIC/WACC0.85

WACC7.55%

2.3 Liquidity

A Current Ratio of 0.76 indicates that XLY may have some problems paying its short term obligations.

The Current ratio of XLY (0.76) is worse than 90.63% of its industry peers.

A Quick Ratio of 0.39 indicates that XLY may have some problems paying its short term obligations.

The Quick ratio of XLY (0.39) is worse than 81.25% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.76
Quick Ratio	0.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XLY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 151.35%, which is quite impressive.

The Revenue has grown by 27.24% in the past year. This is a very strong growth!

Measured over the past years, XLY shows a very strong growth in Revenue. The Revenue has been growing by 71.07% on average per year.

EPS 1Y (TTM)151.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%273.33%

Revenue 1Y (TTM)27.24%

Revenue growth 3Y13.43%

Revenue growth 5Y71.07%

Sales Q2Q%32.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

Based on estimates for the next years, XLY will show a very strong growth in Revenue. The Revenue will grow by 22.57% on average per year.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year18.98%

Revenue Next 2Y26.62%

Revenue Next 3Y26.12%

Revenue Next 5Y22.57%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 4.67, which indicates a rather cheap valuation of XLY.

96.88% of the companies in the same industry are more expensive than XLY, based on the Price/Earnings ratio.

The average S&P500 Price/Earnings ratio is at 27.49. XLY is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	4.67
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XLY indicates a somewhat cheap valuation: XLY is cheaper than 75.00% of the companies listed in the same industry.

Based on the Price/Free Cash Flow ratio, XLY is valued cheaply inside the industry as 84.38% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	9.45
EV/EBITDA	9.71

4.3 Compensation for Growth

The decent profitability rating of XLY may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XLY does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AUXLY CANNABIS GROUP INC

TSX:XLY (10/14/2025, 7:00:00 PM)

0.14

+0.01 (+7.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-14 2025-08-14/bmo

Earnings (Next)11-06 2025-11-06

Inst Owners0.01%

Inst Owner ChangeN/A

Ins Owners4.71%

Ins Owner ChangeN/A

Market Cap188.76M

Analysts45.71

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	4.67
Fwd PE	N/A
P/S	1.35
P/FCF	9.45
P/OCF	8.7
P/B	1.37
P/tB	1.74
EV/EBITDA	9.71

EPS(TTM)0.03

EY21.43%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.01

FCFY10.58%

OCF(TTM)0.02

OCFY11.49%

SpS0.1

BVpS0.1

TBVpS0.08

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	10.86%
ROE	20.44%
ROCE	8.94%
ROIC	6.44%
ROICexc	7.27%
ROICexgc	9.29%
OM	9.65%
PM (TTM)	20.15%
GM	43.74%
FCFM	14.33%

ROA(3y)-20.84%

ROA(5y)-18.51%

ROE(3y)-81.82%

ROE(5y)-60.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y29.45%

GM growth 5YN/A

F-Score6

Asset Turnover0.54

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	3.08
Debt/EBITDA	0.54
Cap/Depr	16.21%
Cap/Sales	1.23%
Interest Coverage	250
Cash Conversion	90.4%
Profit Quality	71.14%
Current Ratio	0.76
Quick Ratio	0.39
Altman-Z	-0.84

F-Score6

WACC7.55%

ROIC/WACC0.85

Cap/Depr(3y)27.93%

Cap/Depr(5y)61.49%

Cap/Sales(3y)4.52%

Cap/Sales(5y)11.68%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)151.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%273.33%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)27.24%

Revenue growth 3Y13.43%

Revenue growth 5Y71.07%

Sales Q2Q%32.17%

Revenue Next Year18.98%

Revenue Next 2Y26.62%

Revenue Next 3Y26.12%

Revenue Next 5Y22.57%

EBIT growth 1Y140.64%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year399.98%

EBIT Next 3Y106.86%

EBIT Next 5Y66%

FCF growth 1Y357.78%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y3342.22%

OCF growth 3YN/A

OCF growth 5YN/A

AUXLY CANNABIS GROUP INC (XLY.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens